DelveInsight’s “Chronic Gout Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Gout market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Chronic Gout market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Gout: An Overview
Gout is a condition in which a waste product called uric acid builds up in the body. Normally, uric acid dissolves in the blood, gets processed by the kidneys, and leaves the body in the urine. A small proportion of uric acid is also excreted by the intestines. With gout, there is too much uric acid in the body, either because the body makes too much uric acid or the kidneys cannot remove as much as they should.
Numerous risk factors for the development of gout have been established, including hyperuricemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use, and chronic renal disease. Common medications include nonsteroidal anti-inflammatory drugs and corticosteroids, another anti-inflammatory. These reduce swelling and pain in the areas affected by gout.
Chronic Gout Market Key Facts
As per DelveInsight, the total prevalent cases of Chronic Gout in the 7MM were 2,355,200+ in 2018.
The market size of Chronic Gout in the 7MM was found to be USD 2,405.3 Million in 2018, which is expected to grow by 2032.
According to the National Kidney Foundation, gout affects 8.3 million adults in the US, which includes 6.1 million men and 2.2 million women.
According to the article by Pisaniello et al. (2018), titled “Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study,” prevalence of gout in the UK, Germany, Canada, US, and New Zealand have varied from 1.4% to 3.9%.
Globally, major pharma giants, such as Selecta Biosciences, Ampel BioSolutions, etc., are involved in developing therapies for the treatment and prevention of Gout.
Several emerging therapies, such as ABP 671 (Jiangsu Atom Bioscience and Pharmaceutical), AR-882 (Arthrosi Therapeutics), TMX-049 (Teijin Limited), etc., are being assessed as potential options to be available in the Chronic Gout market in the coming years.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Gout market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Chronic Gout market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chronic Gout Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Chronic Gout Epidemiology Segmentation
Total Prevalent Cases of Gout
Treatable Prevalent Cases of chronic Gout
Diagnosed Prevalent Cases of Chronic Gout
Diagnosed Prevalent Cases of Gout
Chronic Refractory cases of Gout
Chronic Gout Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Gout market or expected to get launched during the study period. The analysis covers the Chronic Gout market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Gout Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Chronic Gout Market Will Evolve by 2032 @
Several key companies are active in the Chronic Gout therapeutic domain, and the therapies under development are focused on novel approaches to treat the disease.
Some of the key companies in the Chronic Gout Therapeutics Market include:
Sanwa Kagaku Kenkyusho Co. Ltd.
Jiangsu Atom Bioscience and Pharmaceutical
Selecta Biosciences, Inc.
And many others
Chronic Gout Therapies covered in the report include:
Azathioprine: Ampel BioSolutions
SEL-212: Selecta Biosciences
AR882: Arthrosi Therapeutics
ABP 671: Jiangsu Atom Bioscience and Pharmaceutical
TMX-049: Teijin Limited
And many more
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chronic Gout Competitive Intelligence Analysis
4. Chronic Gout Market Overview at a Glance
5. Chronic Gout Disease Background and Overview
6. Chronic Gout Patient Journey
7. Chronic Gout Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Chronic Gout Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Gout Unmet Needs
10. Key Endpoints of Chronic Gout Treatment
11. Chronic Gout Marketed Products
12. Chronic Gout Emerging Drugs and Latest Therapeutic Advances
13. Chronic Gout Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Gout Market Outlook (In US, EU5, and Japan)
16. Chronic Gout Access and Reimbursement Overview
17. KOL Views on the Chronic Gout Market
18. Chronic Gout Market Drivers
19. Chronic Gout Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
Related Reports By DelveInsight
DelveInsight’s “Chronic Gout Pipeline Insight” report provides comprehensive insights into the key companies and emerging drugs in the Chronic Gout pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States